Key result
Asymmetric dimethylarginine (ADMA) is elevated in chronic kidney disease and may play an important role in the pathogenesis of cardiorenal syndrome through endothelial dysfunction.
Population
Patients with cardiorenal syndrome (CRS) and chronic kidney disease (CKD)
Design
Review
Authors
Loading...
Supports ADMA as biomarker in cardiorenal syndrome; leaves open therapeutic targeting pending trials.
This review highlights the potential role of asymmetric dimethylarginine (ADMA) as a biomarker and pathogenic factor linking cardiovascular and renal dysfunction in cardiorenal syndrome.
Ueda et al. (2014) conducted a review in Cardiorenal Syndrome. Asymmetric dimethylarginine (ADMA) was evaluated. Asymmetric dimethylarginine (ADMA) is elevated in chronic kidney disease and may play an important role in the pathogenesis of cardiorenal syndrome through endothelial dysfunction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: